AI Consensus Investment Thesis
Beam Therapeutics (BEAM) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY$30
+21.9%5-Year
BUY$72
+189.1%Latest flagship insight
In Vivo Base Editing Platform Transitions Clinical Proof Into Commercial Dominance
High consensus confirms that proprietary in vivo base editing represents an unpriced technological paradigm shift over legacy CRISPR-Cas9 cutting. While annual cash burn requires disciplined financing, accelerated biomarker approval pathways and liquid balance-sheet reserves through mid-2029 position clinical execution to drive substantial enterprise re-rating.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Elon Musk (Visionary), Warren Buffett (Value Purist), Machiavelli (Insider), Superintelligence (Anthropologist), Universal Investor (Polymath), Sherlock Holmes (Whistleblower), J.P. Morgan (Titan), Ray Dalio (Strategist), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Beam Therapeutics at the forecast anchor (2026-09-18): $28,908 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 25.88 | +3.72% | +3.72% | Year-end tax-loss harvesting and elevated interest rates pressure pre-commercial biotechnology assets, but risto-cel filing preparations and mature clinical durability updates provide underlying support, stabilizing equity valuation near established balance-sheet asset floors. |
| Q1 2027 | 27.18 | +5.05% | +8.96% | Regulatory momentum advances as the risto-cel filing enters formal review, while pivotal enrollment for lead in vivo programs accelerates, reassuring institutional investors and supporting modest equity accumulation despite persistent macroeconomic capital costs. |
| Q2 2027 | 28.29 | +4.05% | +13.37% | Operating expenditures expand as late-stage clinical cohorts scale, prompting brief multiple consolidation. Cash reserves and initial partnership milestone revenues partially offset quarterly research outlays, keeping the trading range orderly. |
| Q3 2027 | 30.42 | +7.53% | +21.91% | Interim biomarker disclosures across in vivo cohorts confirm sustained target engagement without serious hepatotoxicity. Clinical de-risking begins decoupling systemic base editing from cell-therapy peer headwinds, stimulating selective institutional accumulation. |
| Q4 2027 | 32.93 | +8.25% | +31.96% | Anticipation and achievement of regulatory milestones for the lead hematology program validate human base editing fidelity. Valuation expands meaningfully as commercial readiness begins, despite market awareness of transplant conditioning bottlenecks. |
| Q1 2028 | 33.06 | +0.42% | +32.52% | Early commercial rollout reveals logistical throughput limitations in autologous cell therapy, moderating immediate revenue expectations. Increased pre-launch expenditures trigger a temporary valuation consolidation following the initial approval rally. |
| Q2 2028 | 36.20 | +9.48% | +45.08% | Pivotal biomarker readouts in alpha-1 antitrypsin deficiency demonstrate robust functional protein restoration, validating systemic in vivo editing efficacy. Strong clinical proof activates the agreed accelerated approval pathway, sparking substantial institutional accumulation. |
| Q3 2028 | 38.79 | +7.17% | +55.48% | Accelerated approval biologics license submission formalizes commercialization timelines for the lead in vivo asset. Investor focus shifts toward scalable outpatient infusion economics, driving positive multi-quarter multiple expansion. |
| Q4 2028 | 41.38 | +6.66% | +65.84% | Management executes a strategic financing or partnership transaction to fortify commercial balance-sheet reserves. Transient per-share dilution is tempered by the elimination of medium-term refinancing risk into pivotal regulatory decisions. |
| Q1 2029 | 44.04 | +6.44% | +76.52% | Priority review progress and supportive regulatory engagement for in vivo base editing sustain market enthusiasm. Favorable macro financial conditions and stabilizing discount rates provide incremental valuation tailwinds. |
| Q2 2029 | 48.68 | +10.53% | +95.11% | Regulatory approval of the lead in vivo genetic medicine marks a historic technological milestone, unlocking commercial rare-disease monopoly revenues. Institutional re-rating accelerates as high-margin systemic infusions reach diagnosed patient populations. |
| Q3 2029 | 50.50 | +3.74% | +102.40% | Initial commercial distribution metrics confirm strong physician demand and supportive payer reimbursement. High product gross margins begin offsetting corporate research expenditures, cementing an inflection in operating cash flow trajectories. |
| Q4 2029 | 53.50 | +5.95% | +114.45% | Ex-US commercial licensing partnerships inject non-dilutive milestone capital, extending liquidity runway well beyond previous horizons and permanently resolving lingering balance-sheet solvency concerns. |
| Q1 2030 | 55.12 | +3.02% | +120.92% | Commercial revenue expansion continues across specialized centers, while follow-on metabolic clinical pipeline updates demonstrate platform repeatability, reinforcing durable competitive moats and sustaining steady upward valuation drift. |
| Q2 2030 | 58.46 | +6.06% | +134.31% | International regulatory filings and expanding domestic market penetration broaden total addressable revenue. Operational overhead scales moderately, but growing commercial receipts absorb expenses, driving substantial operating leverage. |
| Q3 2030 | 60.34 | +3.22% | +141.86% | Routine market consolidation and seasonal biopharma volume digestion induce modest consolidation. Pipeline advancements in second-generation conditioning platforms provide fundamental support, maintaining an elevated valuation baseline. |
| Q4 2030 | 63.84 | +5.80% | +155.88% | Scaling commercial sales and expanding gross contribution margins narrow quarterly cash burn toward corporate breakeven. Fundamental healthcare allocators expand core equity stakes as commercial execution replaces speculative research milestones. |
| Q1 2031 | 66.33 | +3.89% | +165.84% | Achieving initial operating cash-flow neutrality resets corporate risk perception. Predictable commercial revenue and non-genotoxic conditioning clinical progress drive institutional accumulation, reinforcing through-cycle valuation multiples. |
| Q2 2031 | 69.43 | +4.68% | +178.28% | Label expansion initiatives and advancing Phase 2 readouts across secondary metabolic programs demonstrate sustainable pipeline rejuvenation, supporting compounding equity valuation gains. |
| Q3 2031 | 72.12 | +3.88% | +189.08% | Terminal five-year realization establishes the enterprise as a profitable commercial genetic medicine leader. Durable high-margin sales and an unassailable base-editing patent fortress complete a multi-year valuation rerating. |
The central investment thesis rests on an asymmetric operational transition from capital-intensive, transplant-constrained ex vivo cell engineering toward proprietary, high-margin in vivo base editingbase editingA precise gene-editing technology allowing single-nucleotide changes without inducing double-strand DNA breaks.View full glossary entry. By executing single-nucleotide transitions without inducing double-stranded DNA breaks, the platform evades chromosomal translocations and genotoxic p53 activation, securing superior therapeutic margins over legacy nucleases. Although the market anchors valuation to the sluggish commercialization of first-generation sickle cell therapies, lead asset BEAM-302 addresses alpha-1 antitrypsin deficiency as an off-the-shelf systemic infusion with FDA alignment on surrogate biomarker accelerated approval. With $1.2 billion in cash and debt commitments securing runway into mid-2029, clinical execution can bridge development into commercial cash flows before dilutive restructuring becomes existential.
Key insights
- Direct hepatocyte transfection bypasses myeloablative conditioning, decoupling systemic in vivo genetic medicine from hospital transplant throughput bottlenecks.
- Accelerated approval biomarker endpoints compress registrational review timelines by multi-year increments, significantly expanding discounted net present value.
- Persistent annual free cash consumption of $370 million guarantees secondary equity dilutionequity dilutionThe reduction in ownership percentage for existing shareholders caused by the issuance of new shares.View full glossary entry, moderating per-share equity realization across long horizons.
The company is transforming how genetic diseases are treated by fixing single letters of mutated DNA without breaking genetic strands. While Wall Street worries about the slow rollout of complicated cell therapies that require grueling hospital chemotherapy, the real future lies in simple intravenous infusions targeting liver disorders. Supported by roughly $1.2 billion in cash that funds clinical trials into mid-2029, the business has ample financial runway to prove its treatments work and earn fast-track government approvals before needing fresh outside money.
Key insights
- Simple outpatient infusions replace complicated bone marrow transplants, allowing dramatically more patients to receive treatment quickly.
- Fast-track regulatory review using blood protein markers could pull commercial sales forward by several years.
- Heavy clinical trial spending means future stock offerings could slightly reduce per-share gains for existing investors.
Deep Dive
Prevailing consensus treats the company as a speculative, cash-burning platform biotech burdened by elevated interest rates and sluggish gene therapy rollouts. Media commentary and sell-side notes heavily discount in vivo delivery prospects, anchoring on CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry's slow commercial adoption to dismiss sickle cell upside while assuming heavy clinical trial expenditures will inevitably force punishing shareholder dilution.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing consensus treats the company as a speculative, cash-burning platform biotech burdened by elevated interest rates and sluggish gene therapy rollouts. Media commentary and sell-side notes heavily discount in vivo delivery prospects, anchoring on CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry's slow commercial adoption to dismiss sickle cell upside while assuming heavy clinical trial expenditures will inevitably force punishing shareholder dilution.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value due to an analytical misclassification that conflates ex vivo cell therapy friction with in vivo base-editing scalability. While consensus fixates on myeloablative conditioning bottlenecks in sickle cell disease, it overlooks that BEAM-302 operates as an outpatient systemic infusion with formal regulatory alignment on accelerated biomarker approval. This creates significant underpricing, as the market values the entire enterprise near net liquid assets while assigning negligible value to an uncontested multi-billion-dollar systemic liver monopoly.
Repricing Catalyst
What could make the market recognize and close that gap? Definitive 12-month pivotal cohort biomarker readouts for BEAM-302, demonstrating functional serum protein restoration and toxic polymer clearance, represent the primary trigger. Expected between late 2027 and early 2028 alongside risto-cel regulatory review progress, observable biomarker durability will validate accelerated approval feasibility. This will compel institutional analysts to model near-term commercial cash flows rather than speculative science.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- High Erratic
- Cycle position
- Growing Awareness
Sentiment indicators agree that macroeconomic tightening suppresses clinical-stage biotech multiples, but split between early stabilization and growing awareness. The central tension pits persistent quarterly cash combustion against imminent pivotal biomarker de-risking, governing the exact timing of institutional accumulationinstitutional accumulationSustained net buying by large professional investors such as funds, insurers, and pensions.View full glossary entry.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry of four-percent benchmark policy rates and elevated long-term Treasury yields presents a distinct valuation headwind for long-duration biotechnology equities. High discount rates penalize pre-revenue cash flows. However, the company's $1.2 billion liquid buffer insulates clinical operations from restrictive credit markets, transforming sector liquidity contraction into a relative competitive moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry against undercapitalized peers.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary analytical debate centers on the feasibility and timing of commercial cash flow inflection versus balance-sheet depletion. Bullish perspectives argue that FDA biomarker alignment on BEAM-302 enables accelerated commercial launch by 2028, unlocking high-margin rare-disease revenues that bridge the enterprise to operating self-sufficiency. Conversely, skeptical views emphasize that clinical cash combustion exceeding $370 million annually, combined with sluggish cell therapy adoption and tight monetary conditions, will necessitate dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry offerings that reset per-share valuation. This disagreement will be definitively resolved by FDA acceptance of the accelerated approval filing package in 2027-2028 and initial commercial uptake metrics.
Base-Case Forces
Event Risk ScoreVery High81/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| In Vivo Systemic Base Editingbase editingA precise gene-editing technology allowing single-nucleotide changes without inducing double-strand DNA breaks.View full glossary entry Validation | Innovation And Product | +65% | +85% | Clinical progression of BEAM-302 directly validates systemic in vivo base editingbase editingA precise gene-editing technology allowing single-nucleotide changes without inducing double-strand DNA breaks.View full glossary entry via lipid nanoparticles in humans, concurrently correcting hepatic and pulmonary pathology in alpha-1 antitrypsin deficiency. By executing single-base transitions without double-strand DNA breaks, the platform achieves physiological protein restoration while avoiding chromosomal translocations, establishing superior safety and pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry. |
| Surrogate Biomarker Accelerated Approval Pathway | Regulatory | +45% | +55% | Regulatory alignment with the FDA permitting accelerated approval based on 12-month circulating functional AAT biomarker thresholds significantly compresses clinical development timelines. Bypassing multi-year clinical lung-function decline trials pulls commercial launch forward, reducing cumulative trial expenditures and unlocking high-margin commercial revenue years ahead of traditional orphan-drug review pathways. |
| Fortress Balance Sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry Operational Runway | Capital Allocation | +30% | +20% | Holding $1.2 billion in liquid reserves alongside structured credit capacity provides operational runway extending into mid-2029. This financial insulation eliminates acute refinancing vulnerability during restrictive monetary cycles, enabling management to advance dual pivotal cohorts to commercial inflection without accepting predatory or distressed equity financing terms. |
| Foundational Base Editingbase editingA precise gene-editing technology allowing single-nucleotide changes without inducing double-strand DNA breaks.View full glossary entry Patent Architecture | Competitive Positioning | +25% | +35% | Exclusive foundational intellectual propertyintellectual propertyLegally protected intangible creations such as patents, copyrights, trademarks, designs, trade secrets, and proprietary know-how.View full glossary entry licenses covering adenosine and cytidine base editingbase editingA precise gene-editing technology allowing single-nucleotide changes without inducing double-strand DNA breaks.View full glossary entry establish an impenetrable legal moat against industry entrants. Global pharmaceutical conglomerates seeking non-cleaving genomic correction must license proprietary chemistry, generating substantial non-dilutive milestone inflows, co-development capital, and long-term tollbooth royalties that expand corporate operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Relentless Multi-Hundred-Million Cash Combustion | Capital Allocation | -30% | -35% | Operating losses exceeding $370 million annually reflect heavy clinical commitments across parallel pivotal trials and internal manufacturing infrastructure. Without recurring product revenues, continuous capital consumption steadily depletes liquid reserves, creating unavoidable equity dilutionequity dilutionThe reduction in ownership percentage for existing shareholders caused by the issuance of new shares.View full glossary entry overhang as the corporate development runway approaches commercial launch windows. |
| Ex Vivo Conditioning Commercial Impasse | Sector And Industry | -20% | -25% | Autologous cell therapies like risto-cel face severe real-world adoption friction due to toxic myeloablative busulfan preconditioning, intensive apheresis requirements, and limited specialized transplant center bed capacity. Sluggish market penetration seen across commercialized gene therapies confirms near-term hematology revenues will ramp slowly, constraining early cash generation. |
| Restrictive High Hurdle Rate Valuation Compression | Macroeconomic And Macrofinancial | -18% | -10% | Federal Reserve monetary tightening and benchmark sovereign yields near five percent structurally elevate the cost of capitalcost of capitalCost of capital is the required return investors demand to fund a business, project, or asset, reflecting risk and financing mix.View full glossary entry, penalizing pre-commercial biotechnology assets whose cash flows lie years in the future. High discount rates compress enterprise multiples, muting market appreciation despite positive clinical biomarker achievements. |
| Advanced LNP Scale-Up Manufacturing Complexity | Operational Efficiency | -15% | -20% | Scaling cGMP manufacturing for systemic mRNA-lipid nanoparticle formulations introduces complex chemistry, manufacturing, and controls challenges. Stringent lot-release assays, cold-chain storage logistics, and specialized raw material procurement increase initial unit costs, dampening gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and introducing prospective regulatory audit risks during pivotal registration filings. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Pivotal In Vivo Hepatotoxicity Clinical Hold | 20% | -55% | Emergence of unexpected dose-limiting transaminitis, vector immunogenicity, or off-target deamination in expanded pivotal cohorts prompts an immediate FDA clinical hold on BEAM-302. Such a biological setback would invalidate the systemic in vivo delivery thesis, destroying platform credibility and stranding the business in lower-margin ex vivo niches. |
| Regulatory Rejection of Surrogate Biomarker Endpoints | 25% | -42% | Regulatory agencies reverse guidance and mandate five-year clinical pulmonary decline endpoints rather than circulating AAT restoration for commercial approval. Delaying commercialization into the 2030s would exhaust existing cash reserves before revenue inflection, forcing emergency dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry issuance under punitive market conditions and permanently impairing per-share value. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| First-In-Class Accelerated Approval Triumph | 35% | +75% | A rapid FDA priority review grants accelerated approval for BEAM-302 by 2028 based on definitive 52-week biomarker data, inaugurating the world's first commercial in vivo base editor. This historic regulatory de-risking establishes an uncontested commercial monopoly in severe AATD, driving rapid patient conversion, eliminating external financing requirements, and triggering massive institutional multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. |
| Non-Genotoxic Conditioning Platform Validation | 28% | +65% | Phase 1 clinical proof-of-concept for the ESCAPE platform demonstrates targeted antibody-mediated stem-cell depletion without toxic chemotherapy conditioning. Removing the busulfan barrier transforms ex vivo cell therapies into safe outpatient procedures, expanding the treatable sickle cell population tenfold and unlocking multi-billion-dollar biopharma licensing transactions across non-malignant hematology. |
Company Financial Analysis
Beam Therapeutics Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
The company's headline revenues resemble an irregular burst pattern rather than a traditional business. While trailing twelve-month revenues reached $156 million due to intermittent partnership payments, quarterly receipts plunged to just $490 thousand in mid-2026. This extreme swing occurs because the business has no approved commercial drugs on the market yet, relying entirely on sporadic upfront licensing checks from large pharmaceutical partners. Behind the headline numbers sits a steady clinical engine consuming cash. Trailing operating losses of $378 million and free cash flow burn of $373 million reflect intense development expenditures across parallel human trials. Until proprietary therapies secure regulatory approval and generate commercial sales, reported earnings will remain deeply negative, making clinical milestones far more informative than quarterly accounting profits.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 139.7M | USD -80M | USD -360M |
| 2024 | USD 63.5M | USD -376.7M | USD -356.2M |
| 2023 | USD 377.7M | USD -132.5M | USD -182.9M |
| 2022 | USD 60.9M | USD -289.1M | USD -26.4M |
| 2021 | USD 51.8M | USD -370.6M | USD -113.1M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Examining traditional profit margins today reveals the distorted economics of pre-commercial biotechnology. Operating margins registered at negative 275% in fiscal 2025, swinging alongside lumpy collaboration revenue recognition. While gross margins can appear deceptively high at 84% during milestone quarters, ongoing operational overhead ensures substantial net losses while treatments remain in clinical testing. These negative margins represent intentional developmental investments rather than flawed long-term unit economics. Once systemic in vivo therapies clear regulatory approvals, the underlying economics of precision genetic medicines are expected to yield commercial gross margins exceeding 80%. As commercial product sales scale, high unit profitability should rapidly absorb fixed platform overhead, driving significant operating margin expansion.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -383.7M | -274.6% | -57.2% |
| 2024 | USD -415.6M | -654.3% | -593.1% |
| 2023 | USD -176.5M | -46.7% | -35.1% |
| 2022 | USD -338.5M | -555.6% | -474.5% |
| 2021 | USD -392.5M | -757.0% | -714.9% |
Balance sheet and leverage
AI Review
The corporate balance sheet serves as a vital strategic shield against difficult financial markets. Holding $1.2 billion in liquid cash, cash equivalents, and marketable securities as of mid-2026, the company maintains an exceptional current ratio exceeding 13.0. A conservative debt structure featuring a debt-to-equity ratio of 0.24 protects the business from immediate credit distress or predatory debt covenants. However, headline liquidity must be balanced against ongoing cash burn. Annual operating cash consumption of roughly $370 million gives the business approximately three years of operational autonomy, extending funding into mid-2029. This multi-year cushion enables management to complete critical pivotal clinical trials and seek regulatory approvals without resorting to emergency stock offerings at depressed market prices.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 293.9M | USD 1.2B | USD 1.1M net cash | 13.09x |
| 2024 | USD 161.4M | USD 850.7M | USD 120.5M net cash | 4.82x |
| 2023 | USD 172.7M | USD 1.2B | USD 263.2M net cash | 5.89x |
| 2022 | USD 179M | USD 1.1B | USD 53.8M net cash | 4.89x |
| 2021 | USD 147.6M | USD 965.6M | USD 412.4M net cash | 5.96x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Physical capital spending on brick-and-mortar facilities has moderated substantially, dropping to roughly 11% of recognized revenues after heavy historical investments in internal manufacturing. Management completed construction of its specialized North Carolina cGMP production plant early, which now insulates the pipeline from third-party manufacturing bottlenecks without requiring major new facility construction outlays during current high-interest periods. Instead, true investment intensity is concentrated in scientific human capital and clinical trial execution. Annual research and development expenditures consistently absorb approximately $400 million, financing patient enrollment, lipid nanoparticle formulation, and rigorous safety bioanalytics. This strategic allocation preserves physical capital while channeling corporate resources directly into building valuable, patent-protected clinical assets.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 14.9M | USD 409.6M |
| 2024 | USD 8.9M | USD 367.6M |
| 2023 | USD 33.7M | USD 437.4M |
| 2022 | USD 49M | USD 311.6M |
| 2021 | USD 46.8M | USD 387.1M |
Quarterly Forecast Scenarios
Beam Therapeutics Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $23.70 | $25.91 | $27.45 | $750.26 | |
| $24.41 | $27.29 | $30.18 | $736.44 | |
| $25.64 | $28.38 | $31.99 | $743.40 | |
| $26.15 | $30.67 | $37.75 | $755.15 | |
| $27.72 | $33.20 | $40.12 | $776.22 | |
| $26.61 | $33.09 | $42.12 | $787.13 | |
| $27.41 | $36.47 | $45.91 | $802.83 | |
| $28.78 | $39.03 | $48.67 | $812.05 | |
| $29.89 | $41.85 | $57.43 | $839.18 | |
| $29.59 | $44.83 | $61.66 | $850.50 | |
| $30.77 | $49.65 | $75.23 | $872.39 | |
| $31.70 | $51.86 | $81.25 | $885.51 | |
| $32.96 | $55.25 | $90.18 | $909.56 | |
| $33.62 | $56.66 | $86.58 | $916.13 | |
| $34.63 | $60.15 | $94.37 | $936.51 | |
| $37.06 | $62.81 | $105.69 | $947.34 | |
| $38.17 | $66.78 | $114.15 | $969.59 | |
| $38.93 | $69.89 | $125.56 | $979.99 | |
| $40.49 | $73.26 | $134.35 | $999.60 | |
| $41.30 | $76.35 | $142.41 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The evidentiary consensus establishes a profound structural bifurcation: while first-generation ex vivo cell therapy faces severe commercial constraints due to toxic conditioning and transplant center bottlenecks, systemic in vivo base editing demonstrates transformative clinical efficacy. Reports rigorously grounded in primary SEC filings, audited liquidity metrics, and verified clinical congress readouts receive the highest weightings. These inputs correctly account for an annual cash burn of approximately $370 million, floating-rate debt obligations, and inevitable equity dilution schedules that cap per-share compounding. Conversely, reports projecting frictionless multi-billion-dollar commercial ramps or unmitigated multiple expansion are downweighted for underestimating macro duration penalties under elevated policy rates. The credible contrarian case warns that surrogate biomarker rejection or emergent lipid nanoparticle hepatotoxicity could trigger regulatory holds and liquidity exhaustion. Relative weights prioritize analytical discipline that balances definitive in vivo biomarker de-risking against unavoidable equity dilution and operational capital intensity through 2029.
Universal Investor AI
The Polymath
Opus 5Exceptional evidentiary grounding utilizing audited SEC filings, ERS congress clinical data, and peer commercial benchmarks. Rigorously accounts for per-share equity dilution schedules, floating-rate debt drag, and real-world cell therapy capacity constraints, establishing superior causal credibility.
Michael Burry AI
The Vulture
Gemini 3.8 FlashOffers rigorous balance-sheet scrutiny, anchoring on cash-backed downside asset protection and replacement cost of intellectual property. Recognizes the structural inflection from ex vivo cell therapy to systemic in vivo delivery, though assumes slightly accelerated commercial uptake schedules in alpha-1 antitrypsin deficiency.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashAnchors on rigorous fundamental valuation, contrasting net liquid assets per share against enterprise replacement costs. Cites verified clinical trial disclosures while properly penalizing long-duration cash flows for cost of capital and clinical development delays.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashCombines acute forensic attention to credit facility covenants and cash burn with realistic appraisal of surrogate biomarker endpoints. Accurately identifies the accelerated approval mechanism as the critical valuation bridge, balancing regulatory upside against severe clinical execution risks.
Universal Investor AI
The Polymath
Gemini 3.8 FlashDelivers robust multi-dimensional analysis linking surrogate biomarker readouts to accelerated biologics licensing timelines. Integrates primary SEC disclosures and liquidity runway data effectively, providing a balanced synthesis between scientific breakthrough potential and persistent macroeconomic multiple compression.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashPresents strong macroeconomic regime framing, mapping the impact of four-percent benchmark rates onto long-duration biological assets. Successfully demonstrates how balance-sheet liquidity insulates clinical trials from external credit freezes, though slightly understates unit-level cell therapy commercial friction.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashProvides sharp strategic analysis of regulatory alignment on surrogate endpoints and institutional pricing friction. Accurately maps the transition from ex vivo transplantation bottlenecks to outpatient in vivo infusions, backed by solid capital runway verification.
Universal Investor AI
The Polymath
Gemini 3.8 FlashProvides a measured framework balancing clinical de-risking against ongoing operating cash burn. Properly highlights the genotoxic safety advantages of single-base transition chemistry over double-strand breaks while accurately forecasting that secondary equity offerings will temper long-term per-share compounding.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashExhibits strong discipline regarding negative owner earnings, capital allocation, and valuation sensitivity to high risk-free interest rates. Correctly identifies the non-genotoxic conditioning platform as an unpriced competitive option, though somewhat understates the near-term clinical velocity of the in vivo pipeline.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashThoroughly details registrational timeline dynamics across lead clinical programs, supported by primary medical disclosures. However, it overweights peak sovereign market potential while minimizing commercial friction in cell therapy distribution and persistent discount-rate headwinds in valuation models.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashArticulates the civilizational shift toward precision base editing with strong biological insight, though exhibits minor narrative optimism regarding global commercialization pacing. Demonstrates consistent reasoning regarding cash runway insulation and regulatory milestone catalysts.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashPresents sound analysis of in vivo base-editing differentiation versus Cas9 cutting, but incorporates aggressive long-term valuation compounding without adequate modeling of near-term dilution mechanics. Qualitative arguments are causally coherent but lack balanced balance-sheet sensitivity checks relative to more disciplined financial inputs.
Elon Musk AI
The Visionary
Gemini 3.8 FlashCaptures the technological leap of direct hepatocyte transfection via lipid nanoparticles, yet applies overly enthusiastic adoption timelines and terminal multiples. Underplays the real-world friction of clinical trial enrollment and specialized hospital administration logistics during launch phases.
Universal Investor AI
The Polymath
GPT-6 AstraProvides thorough financial analysis, but assigns disproportionately high probability to standalone event impacts and includes speculative robotics claims. Its resulting return checkpoints diverge materially from the balanced consensus path, warranting a lower relative weighting.
Research Provenance
References & Context
This Beam Therapeutics consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 84 deduplicated sources retained for this batch.
- 01Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing | FDAfda.gov
- 02Beam Therapeutics Inc. - Form 8-K - FY2026sec.gov
- 03Beam Therapeutics Inc. - Form 8-K - FY2026sec.gov
- 04Beam Therapeutics Inc. - Form 8-K - FY2026sec.gov
- 05EDGAR Filing Documents for 0001193125-26-331541sec.gov
- 06vrtx-20260630sec.gov
- 07New Data on BEAM-302 for AATD Presented - BEAM | BioPharmaWatchbiopharmawatch.com
- 08Beam one-ups Wave as both show promise of genetic editing for AATD - BioSpacebiospace.com
- 09Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In - BioSpacebiospace.com
- 10Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer - BioSpacebiospace.com
- 11News: Rival Editors Converge on AATD as Data Mount - CRISPR Medicinecrisprmedicinenews.com
- 12Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration | Beam Therapeuticsinvestors.beamtx.com
- 13Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Beam Therapeuticsinvestors.beamtx.com
- 14Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference | Beam Therapeuticsinvestors.beamtx.com
- 15Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | Beam Therapeuticsinvestors.beamtx.com
And 69 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2017-12-31–2025-12-31, 9 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.